Drug Discovery and the Market Today: Video Exclusive with Dr. David Elder, GSK
06/11/2010
David Elder | drug discovery | stability testing | solubility | amorphous forms | genotoxic and carcinogenic impurities | externalization
David Elder | drug discovery | stability testing | solubility | amorphous forms | genotoxic and carcinogenic impurities | externalization
Dr. David Elder, the Externalization Director for GlaxoSmithKline, talks exclusively to Pharma IQ on his perspective across the industry, including CROs, regulations, and strategising for efficiency.
-
BHC- Product Supply: Pipeline Transparency & Risk Asssessment -
Recent Developments in Optimised Forecast Accuracy, Sales and Operations Planning at Merck Serono -
Safety Assessment of Novel Respiratory Delivery Systems: Lessons from the Exubera® Development Program -
Contractor Management -
Cold Chain Management -
Drug Discovery and the Market Today Part 4: Developing Amorphous Forms -
Drug Discovery and the Market Today Part 5: Considering Genotoxic and Carcinogenic Impurities -
Drug Discovery and the Market Today Part 2: Critical Thoughts on Stability -
Drug Discovery and the Market Today Part 3: The Focus on Solubility -
Drug Discovery and the Market Today Part 1: An Overview of Externalisation in the Pharma Industry
You Should Check Out:
* = required.
Not a member yet? Sign up
Events of Interest
-
Stability Testing Training Online 2011
August 30, 2011
Register Now -
hESC derived Cytiva™ Cardiomyocytes for Drug Safety Testing
March 28, 2012
Register Now -
Enhancing the Bioavailability of Low-Solubility Compounds
February 18, 2010
Register Now -
Adverse Event Reporting Online Training Course 2011
August 3, 2011
Register Now




Not a member? Sign Up
Reasons for Joining
Address your challenges through knowledge sharing with peers from our global network of specialists.
Benchmark your business initiatives with the who's who in the field.
Hear from industry pioneers how to maximize ROI in today's challenging economy.
And best of all It's FREE!